HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Magro, A. M. Articles by Alexander, A. Search for Related Content PubMed Articles by Magro, A. M. Articles by Alexander, A.

In Vitro Studies of Histamine Release from Rabbit Leukocytes by Divalent Haptens¹

From the Department of Medical Immunology, The Public Health Research Institute of the City of New York, Inc., New York, New York 10016

Abstract

The in vitro histamine release by washed leukocytes from rabbits immunized to produce reagin specific for the benzyl penicillolyl (BPO) and the 2,4 dinitrophenyl (DNP) haptenic groups was studied. The animals were immunized to produce reagin specific for one of the haptenic groups (DNP or BPO) and for both haptenic groups (DNP and BPO). The divalent and univalent haptens used to initiate histamine release from the leukocytes were bis-DNP-octamethylenediamine (di-DNP), DNP-n-octylamine (uniDNP), bis-BPO-octamethylenediamine (diBPO), BPO-n-octylamine (uniBPO) and N-DNP,N-BPO, octamethylenediamine (mixed BPO-DNP).

The data indicate that 1) reagin of both specificities is on the majority of the basophils of rabbits immunized to both DNP and BPO; 2) the reagin on the basophil surface is not grouped by specificity; 3) internal bridging between two Fab pieces of a single reaginic antibody molecule is probably not a basic mechanism by which histamine is released; and 4) the hapten must bridge the membrane bound reaginic antibody to another point away from the antibody molecule in order for the hapten specific release of histamine to be initiated.

Footnotes

¹ This work was supported by National Science Foundation Grant GB-31738X; American Cancer Society, Inc., Grant IC-391, and United States Public Health Service Grants AI-08719 and AI-10455.

² Supported by United States Public Health Service Training Grant AI-408-02. Address reprint requests to Dr. Magro.